Pediatrics · LP-019
Sulfamethoxazole + Trimethoprim Oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-019Pediatrics
- Generic identity
- Sulfamethoxazole + TrimethoprimOral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-019
- Generic identity
- Sulfamethoxazole + Trimethoprim
- Presentation
- Oral suspension
- Catalogue strength
- 200 mg + 40 mg/5 mL
- Catalogue pack
- Bottle 60 mL / 100 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic combination identity: sulfamethoxazole + trimethoprim.
- Dosage form: oral suspension.
- Catalogue concentration: 200 mg + 40 mg per 5 mL.
- Catalogue bottle options: 60 mL and 100 mL.
- Catalogue category: Pediatrics; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Chemical forms/basis and quantitative excipient/suspension formula.
- Approved indication, age/weight eligibility, dose instructions and current contraindications/warnings for the exact jurisdiction.
- Shaking/measuring-device instructions, after-opening storage and bottle-specific SKU evidence.
- Registration, manufacturing route, shelf life and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg + 40 mg/5 mL | Oral suspension | — | Bottle 60 mL | Age eligibility, exact formula and pack approval require controlled product documents. |
| B | 200 mg + 40 mg/5 mL | Oral suspension | — | Bottle 100 mL | Age eligibility, exact formula and pack approval require controlled product documents. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Sulfamethoxazole with trimethoprim, also called co-trimoxazole, combines two antimicrobial ingredients with complementary effects on microbial folate metabolism. It is used for selected susceptible infections and has important allergy, interaction and laboratory-monitoring considerations. A liquid and a tablet are separate presentations of the combination. This page provides general ingredient education, not a Luang Pharma approved indication or a recommendation for self-treatment.
Clinical context and therapeutic role
Its place in therapy depends on the infection, patient immune status, microbiology and local guidance. Some uses require specialist supervision, particularly in immunocompromised patients. The prescriber should consider alternative agents, kidney function, blood disorders and the person’s complete medication list. The catalogue’s strength ratio must be checked against the actual registered presentation. New or worsening respiratory symptoms during treatment deserve prompt clinical attention, not attribution to the infection alone.
Selected safety context
Important risks include severe skin reactions, blood-cell disorders, high potassium, kidney injury and serious allergy. Suspected sulfonamide or trimethoprim allergy, pregnancy, infancy, folate deficiency and glucose-6-phosphate dehydrogenase deficiency require professional assessment. Interactions with warfarin, methotrexate and potassium-raising medicines can be clinically significant. A rash with blisters, fever, unusual bruising, breathlessness, jaundice or marked weakness warrants urgent review. A professional may require laboratory monitoring according to the clinical setting.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies an oral suspension. A measured volume is meaningful only with the verified concentration and correct mixing instructions. The suspension vehicle, excipients and product-specific behavior cannot be inferred from the ingredient name, and different concentrations must not be compared using volume alone.
Follow the approved instructions for shaking and use a suitable calibrated oral device. Keep the bottle properly closed and labeled. Storage conditions and the permitted period after opening must be established from the actual supplied product; this profile does not assign either.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Controlled formula/specification confirming both component quantities and chemical forms.
Approved label/leaflet with age/indication, measuring/shaking and safety information.
Bottle/closure/measuring-device specification and pack/SKU matrix.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| DailyMed: Sulfamethoxazole and trimethoprim suspension — official US label exampleArchived source classification: US official drug label example | Source revision recorded: Label updated 6 March 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| MedlinePlus: Co-trimoxazoleArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-019.
Professional enquiries
Request product-specific evidence for LP-019.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.